Ferring and Blackstone jointly invest in a new bladder cancer therapy
Category: #health  By Pankaj Singh  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ferring and Blackstone jointly invest in a new  bladder cancer therapy

Private investment firm, Blackstone Life Sciences and Ferring Pharmaceuticals recently announced joint investment of more than USD 570 million in a novel investigational  gene therapy, rAd-IFN/Syn3 (nadofaragene firadenovec). The therapy is being developed for the treatment of patients with high-grade BCG (Bacillus Calmette-Guérin) unresponsive and NMIBC (non-muscle invasive bladder cancer).

Ferring has created a new gene therapy company and Ferring subsidiary, FerGene to potentially commercialize rAd-IFN/Syn3 in the U.S. and to advance the global clinical development. FerGene’s aim is to acquaint patient population with this promising therapy. Ferring will invest up to USD 170 million and Blackstone will invest USD 400 million in FerGene. Ferring is also expected to potentially launch & commercialize rAd-IFN/Syn3 outside of the U.S.

Currently in late Phase 3 development, rAd-IFN/Syn3 has been granted Breakthrough Therapy designation and had its Biologics License Application  accepted for filing and granted Priority Review by the Food and Drug Administration.

Frederik Paulsen, Chairman of Ferring Pharmaceuticals, was reportedly quoted saying that it requires dedicated focus and capabilities to bring a novel gene therapy to the market. FerGene, will aid Ferring Pharmaceuticals with the resources & team needed to potentially bring rAd-IFN/Syn3 to patients.

Paulsen added that through this new joint financing model between Blackstone Life Sciences and Ferring, the company aims to ensure that more and more people with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer may benefit from this novel gene therapy, if it is approved.

Phase 3 clinical trial results for nadofaragene firadenovec will be presented at the SUO (Society of Urologic Oncology) 20th Annual Meet in Washington, DC. FerGene will hold the marketing authorization of nadofaragene firadenovec, upon the potential FDA approval.

Dr. Stephen A. Boorjian, Professor of Urology at Mayo Clinic in Rochester and the Coordinating Investigator for the trial was reported to state that this trial expands the potential for search of effective alternatives to cystectomy for patients with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer, which can significantly improve patient care in future.
 

Source Credit: https://www.blackstone.com/media/press-releases/article/ferring-and-blackstone-life-sciences-invest-over-$570-million-usd-in-novel-gene-therapy-for-bladder-cancer-patients



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...